The cyclin kinase inhibitor p57 kip2 regulates TGF-β-induced compensatory tubular hypertrophy: Effect of the immunomodulator AS101

Nephrology Dialysis Transplantation

Volumn 24, Issue 8, 2009, Pages 2328-2338

  Sinuani, Inna ^a,b   Weissgarten, Joshua ^a   Beberashvili, Ilia ^a   Rapoport, Micha J ^a   Sandbank, Judit ^a   Feldman, Leonid ^a   Albeck, Michael ^b   Averbukh, Zhan ^a   Sredni, Benjamin ^b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Cell cycle; Compensatory renal growth; Cyclin kinase inhibitor proteins; Hypertrophy; Transforming growth factor

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN E; CYCLINE; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; KIDNEY HYPERTROPHY; KIDNEY MASS; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DNA; ETHYLENES; GENE EXPRESSION REGULATION; HYPERTROPHY; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTERLEUKIN-10; KIDNEY TUBULES; MALE; NEPHRECTOMY; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 67651100779     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn742     Document Type: Article

References (52)

1. Fine LG, Norman JT. Renal growth responses to acute and chronic injury: routes to therapeutic intervention. J Am Soc Nephrol 1992; 2: S202-S211
2. Liu B, Preisig PA. Compensatory renal tubular hypertrophy is mediated by a cell cycle-dependent mechanism. Kidney Int 2002; 62: 1650-1657
3. Shankland SJ. Cell cycle regulatory proteins in glomerular disease. Kidney Int 1999; 56: 1208-1215
4. kip1. Kidney Int 1999; 56: 1262-1265
5. Schoecklmann HO, Rupprecht HD, Zauner I et al. TGF-beta-1-induced cell cycle arrest in renalmesangial cells involves inhibition of cyclin E/cdk2 activation and retinoblastoma protein phosphorylation. Kidney Int 1997; 51: 1228-1236
6. Liu B, Preisig PA. TGF-β-mediated hypertrophy in rat renal epithelial cells involves inhibiting phosphorylation by preventing activation of cdk2/cyclin E kinase. Am J Physiol 1999; 277: F186-F194
7. Franch HA, Shay JW, Alpern RJ et al. Involvement of pRb family in TGF-β dependent epithelial cell hypertrophy. 1995; J Cell Biol 129: 245-254
8. Huang HC, Preisig PA. Cyclin D kinase is activated in all diabetic renal growth, while cyclin E kinase determines whether the growth pattern will hyperplasia or hypertrophy [Abstract]. Am J Soc Nephrol 1998; 9: 440
9. Morgan DO. Principles of CDK regulation. Nature 1995; 374: 131-134
10. kip1. Kidney Int 1997; 51: 1088-1099
11. Wolf G, Nelson EG. Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia. Kidney Int 1991; 39: 401-420
12. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6: 597-631
13. Blobe GC, Schiemann WP, Lodish FH. Role of transforming growth factor β in human disease. N Engl J Med 2000; 342: 1350-1358
14. Tamaki K, Okuda S, Ando T et al. TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int 1994; 45: 525-536
15. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003; 23: 532-543
16. Hoffman BB, Sharma K, Ziyadeh FN. Potential role of TGF-beta in diabetic nephropathy. Miner Electrol Metab 1998; 24: 190-196
17. Fujita H, Omori S, Ishikura K et al. ERK and p38 mediated highglucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am J Physiol Renal Physiol 2004; 286: F120-F126
18. Choi ME, Kim EG, Huang Q et al. Rat mesangial cell hypertrophy in response to transforming growth factor-beta 1. Kidney Int 1993; 44: 948-958
19. Wolf G, Mueller E, Stahl RA et al. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92: 1366-1372
20. Preisig PA, Franch HA. Renal epithelial cell hyperplasia and hypertrophy. Semin Nephrol 1995; 15: 327-340
21. Preisig PA. A cell cycle-dependent mechanism of renal tubule epithelial cell hypertrophy. Kidney Int 1999; 56: 1193-1198
22. Preisig PA. Renal hypertrophy and hyperplasia. In: Selden DW and Giebisch G (eds). The Kidney: Physiology and Pathophysiology. Philadelphia: Lippincott Williams and Wilkins, 2000, 727-748
23. Strassmann G, Kambayashi T, Jakob CO et al. The immunomodulator AS101 inhibits IL-10 release and augments TNF-alpha and IL-1 alpha release by mouse and human mononuclear phagocytes. Cell Immunol 1997; 176: 180-185
24. Sredni B, Caspi RR, Klein A et al. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 1987; 330: 173-176
25. Kalechman Y, Sredni B, Weinstein T et al. Production of novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101: role in experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 2003; 15: 354-361
26. Sredni B, Tichler T, Shani A et al. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. J Natl Cancer Inst 1996; 88: 1276-1280
27. Kalechman Y, Gafter U, Da JP et al. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101. J Immunol 1997; 159: 2658-2667
28. Sinuani I, Averbukh Z, Gitelman I et al. Mesangial cells initiate compensatory renal tubular hypertrophy via IL-10 induced TGF-β secretion: Effect of the immunomodulator AS101 on this process. Am J Physiol Renal Physiol 2006; 291: F384-F394
29. Park SK, Kang SK, Lee DY et al. Temporal expression of cyclins and cyclin dependent kinases during renal development and compensatory growth. Kidney Int 1997; 51: 762-769
30. Shankland SJ, Hamel PA, Scholey JW. Cyclin and cyclin dependent kinase expression in the remnant glomerulus. J Am Soc Nephrol 1996; 8: 368-375
31. kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 1998; 54: 1923-1933
32. kip1. Kidney Int 1996; 50: 2112-2119
33. kip1. Kidney Int 1999; 56: 1262-1265
34. kip1 and p21Cip1) cause hypertrophy in LLC-PK1 cells. Kidney Int 1999; 56: 494-501
35. Al'Douahji M, Bruganolis, Brown PAJ. The cyclin kinase inhibitor p21Waf/Cip1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 1999; 56: 1691-1699
36. Kim YG, Alpers CE, Brugarolas J et al. The cyclin kinase inhibitor p21Waf1/Cip1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis. Kidney Int 1999; 55: 2349-2361
37. Kuan CJ, al-Douahji M, Shankland SJ. The cyclin kinase inhibitor p21 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 1998; 9: 986-993
38. Waga S, Hannon HJ, Beach D et al. The p21 inhibitor of cyclindependent kinases controls DNA replication with PCNA. Nature 1994; 69: 574-578
39. Kitagawa M, Higashi H, Jung HK. The consensus motif for phosphorylation by cyclin D1-cdk4 is different from that for phosphorylation by cyclinA/E-cdk2. EMBO J 1996; 15: 7060-7069
40. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 2235-2243
41. Shankland SJ. Cell-cycle control and renal disease. Kidney Int 1997; 52: 294-308
42. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990; 344: 503-508
43. Connel-Growley L, Harper JW, Goodrich DW. Cyclin D/cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Cell Biol 1997; 8: 287-301
44. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18: 753-761
45. Ezhevsky SA, Nagahara H, Vocero-Akbani AM et al. Hypophosphorylation of the retinoblastoma protein (pRB) by cyclin D-cdk 4,6 complexes results in active pRB. Proc Natl Acad Sci 1997; 94: 10699-10704
46. Resnitzky D, Gossen M, Bujart H et al. Acceleration of the G1/S phase transition by expression of cyclin D and cyclin E with inducible system. Mol Cell Biol 1994; 14: 1669-1679
47. Nagahara H, Ezhevsky SA, Vocero-Akbani AM et al. Transforming growth factor β targeted inactivation of cyclin E: cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity. Proc Natl Acad Sci. 1999; 96: 14961-14966
48. kip2 up-regulation. Proc Natl Acad Sci 2004; 101: 15231-15236
49. Chen Z, Li DQ, Tong L et al. Targeted inhibition of p57 and p15 blocks transforming growth factor beta-inhibited proliferation of primary cultured human limbal epithelial cells. Mol Vis 2006; 23: 983-994
50. kip2 is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor β1. J Biol Chem 1999; 274: 12197-12200
51. Nishimori S, Tanaka Y, Chiba T et al. Smad-mediated transcription is regulated for transforming growth factor-beta 1-induced p57(kip2) proteolysis in osteoblastic cells. J Biol Chem 2001; 276: 10700-10705
52. Urano T, Hosoi T, Shiraki M et al. Possible involvement of the p57(Kip2) gene in bone metabolism. Biochem Biophys Res Commun 2000; 269: 422-426